Edition:
United States

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

50.35USD
22 Oct 2018
Change (% chg)

$-0.95 (-1.85%)
Prev Close
$51.30
Open
$51.70
Day's High
$51.70
Day's Low
$49.69
Volume
106,349
Avg. Vol
137,290
52-wk High
$59.54
52-wk Low
$32.62

Latest Key Developments (Source: Significant Developments)

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes
Monday, 4 Jun 2018 07:00am EDT 

June 4 (Reuters) - Acceleron Pharma Inc ::ACCELERON ANNOUNCES UPDATED RESULTS FROM ONGOING PHASE 2 TRIALS OF LUSPATERCEPT IN MYELODYSPLASTIC SYNDROMES AT THE ASCO 2018 ANNUAL MEETING.ACCELERON PHARMA INC - 55% OF PATIENTS ACHIEVED A CLINICALLY MEANINGFUL ERYTHROID IMPROVEMENT.ACCELERON PHARMA INC - 44% OF PATIENTS WITH A RED BLOOD CELL TRANSFUSION BURDEN AT BASELINE ACHIEVED TRANSFUSION INDEPENDENCE.ACCELERON PHARMA INC - MULTIPLE PATIENTS CONTINUE TO SUSTAIN CLINICALLY MEANINGFUL INCREASE IN HEMOGLOBIN AND REDUCTION IN TRANSFUSION BURDEN.  Full Article

Acceleron Begins Phase 2 Trial Of Pulmonary Arterial Hypertension Treatment
Tuesday, 22 May 2018 07:00am EDT 

May 22 (Reuters) - Acceleron Pharma Inc ::ACCELERON ANNOUNCES INITIATION OF PULSAR PHASE 2 TRIAL OF SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION.ACCELERON PHARMA - PLANS TO REPORT PRELIMINARY RESULTS FROM 6-MONTH PRIMARY TREATMENT PERIOD OF PULSAR PHASE 2 TRIAL IN FIRST HALF OF 2020.  Full Article

Acceleron Reports Q1 Loss Per Share $0.58
Tuesday, 8 May 2018 04:01pm EDT 

May 8 (Reuters) - Acceleron Pharma Inc ::ACCELERON REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS.ACCELERON PHARMA - BELIEVES EXISTING CASH, CASH EQUIVALENTS & INVESTMENTS TO BE SUFFICIENT TO FUND PROJECTED OPERATING REQUIREMENTS INTO 2021.ACCELERON PHARMA INC - QTRLY LOSS PER SHARE $0.58.ACCELERON PHARMA INC - QTRLY COLLABORATION REVENUE $3.2 MILLION VERSUS $3.7 MILLION.  Full Article

Acceleron Pharma Q4 Loss Per Share $‍0.62​
Tuesday, 27 Feb 2018 04:05pm EST 

Feb 27 (Reuters) - Acceleron Pharma Inc ::ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS.‍TOP-LINE RESULTS FROM MEDALIST AND BELIEVE PHASE 3 TRIALS OF LUSPATERCEPT ARE EXPECTED IN MID-2018​.‍ON TRACK TO INITIATE A PHASE 2 TRIAL IN PULMONARY ARTERIAL HYPERTENSION IN 1H 2018​.QTRLY LOSS PER SHARE $‍0.62​.  Full Article

Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018
Monday, 8 Jan 2018 09:00am EST 

Jan 8 (Reuters) - Acceleron Pharma Inc ::ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018.ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH FACIOSCAPULOHUMERAL DYSTROPHY.  Full Article

Acceleron Pharma qtrly net loss per share $0.65
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports third quarter 2017 operational and financial results.Acceleron Pharma Inc - ‍existing cash, cash equivalents and investments will be sufficient to fund projected operating requirements into 2021​.Acceleron Pharma Inc qtrly net loss per share applicable to common stockholders basic and diluted $0.65.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron announces pricing of public offering of common stock
Wednesday, 20 Sep 2017 08:31pm EDT 

Sept 20 (Reuters) - Acceleron Pharma Inc :Acceleron announces pricing of public offering of common stock.Acceleron Pharma - Announced underwritten public offering of 5.4 million shares of common stock at a price to public of $37 per share.  Full Article

Acceleron announces proposed public offering of common stock
Tuesday, 19 Sep 2017 04:12pm EDT 

Sept 19 (Reuters) - Acceleron Pharma Inc :Acceleron announces proposed public offering of common stock.Acceleron Pharma Inc - Announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock.Acceleron Pharma - Intends to use net proceeds from offering to conduct clinical trials and associated activities.  Full Article

Acceleron Pharma Q2 loss per share $0.77
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports second quarter 2017 operational and financial results.Qtrly loss per share $0.77.Acceleron Pharma Inc - collaboration revenue for Q2 was $3.1 million..  Full Article

Acceleron announces first patient treated in phase 2 clinical trial of ACE-083
Tuesday, 1 Aug 2017 07:00am EDT 

Aug 1 (Reuters) - Acceleron Pharma Inc :Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease.  Full Article

BRIEF-Acceleron Begins Phase 2 Trial Of Pulmonary Arterial Hypertension Treatment

* ACCELERON ANNOUNCES INITIATION OF PULSAR PHASE 2 TRIAL OF SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION